Publications

Phase I trial of HuMab-5B1 (MVT-5873), a novel monoclonal antibody targeting sLea, in patients with advanced pancreatic cancer and other CA19-9 positive malignancies

EM O'Reilly, TM Bauer, J Infante, JC Gutheil, P Klein, KH Yu, MA Lowery, ...

Presentation, clinical behavior, outcomes and therapies for patients with advanced pancreas adenocarcinoma (PAC) who present with or develop ascites.

A Mier Hicks, EM O'Reilly, M Capanu, MA Lowery, KH Yu

ReCAP: hospitalizations in older adults with advanced cancer: the role of chemotherapy

CB O’Neill, CL Atoria, EM O’Reilly, MC Henman, PB Bach, EB Elkin, ...

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer …

EM O'Reilly, D Mahalingam, JM Roach, PJ Miller, ME Rosano, S Krause, ...

Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.

MA Lowery, LW Goff, E Jordan, R Wang, AG Bocobo, JF Chou, ...

Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.

LW Goff, MA Lowery, E Jordan, R Wang, AG Bocobo, JF Chou, ...

Texture analysis for survival prediction of pancreatic ductal adenocarcinoma patients with neoadjuvant chemotherapy

J Chakraborty, L Langdon-Embry, JG Escalon, PJ Allen, MA Lowery, ...

Weight loss, diabetes, fatigue, and depression preceding pancreatic cancer

SH Olson, Y Xu, K Herzog, A Saldia, EM DeFilippis, P Li, PJ Allen, ...

Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas

LH Tang, BR Untch, DL Reidy, E O'Reilly, D Dhall, L Jih, O Basturk, ...

Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas (vol 22 …

LH Tang, BR Untch, DL Reidy, E O'Reilly, D Dhall, L Jih

‘We have to discuss it’: cancer patients' advance care planning impressions following educational information about cardiopulmonary resuscitation

AS Epstein, E Shuk, EM O'reilly, KA Gary, AE Volandes

“Months, not years”: Impact of clinical discussions of advanced cancer life-expectancy on patient illness understanding.

AS Epstein, HG Prigerson, L Saltz, EM O'Reilly, MA Shah, PK Maciejewski

“This is not me”: patient, family, cultural and clinician considerations in cases of severe cancer-related debility

D Li, GK Abou-Alfa, AD Viny, M Cammarata, A Shamseddine, A Al-Olayan, ...

90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

VJ Picozzi, RK Ramanathan, MA Lowery, AJ Ocean, EP Mitchel, ...

A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC).

MA Lowery, EM O'Reilly, JJ Harding, E Salehi, E Hollywood, M Bradley, ...

Abstract B98: Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior …

VJ Picozzi, RK Ramanathan, MA Lowery, AJ Ocean, EP Mitchell, ...

Abstract IA28: BRCA-mutated pancreas adenocarcinoma: Emerging therapeutic implications

EM O'Reilly

Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma

D Li, EM O’Reilly

Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).

JM Clarke, H Pang, MD Starr, AJ Hatch, HL Kindler, EM O'Reilly, ...

EBV-associated lymphoepithelioma-like carcinoma of the pancreas: case report with targeted sequencing analysis

RT Samdani, JF Hechtman, E O'Reilly, R DeMatteo, CS Sigel

Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies

VJ Picozzi, RK Ramanathan, MA Lowery, AJ Ocean, EP Mitchell, ...

Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+ Gem) in …

EM O'Reilly, LS Smith, JC Bendell, JH Strickler, M Zalupski, W Gluck, ...

FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma

E Sadot, A Doussot, EM O’Reilly, MA Lowery, KA Goodman, RKG Do, ...

Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer

Nagaraju GP, Long TE, Park W, Landry JC, Taliaferro-Smith LT, Farris AB, …

Hepatocellular carcinoma (HCC) and bone metastases (Mets).

JJ Harding, G Abu Zeinah, JF Chou, DH Owen, M Ly, MA Lowery, ...

Identification of germline genetic mutations in patients with pancreatic cancer

EE Salo‐Mullen, EM O'Reilly, DP Kelsen, AM Ashraf, MA Lowery, KH Yu, ...

Intensity-modulated radiation therapy (IMRT) in patients with locally advanced pancreatic cancer (LAPC).

C Hajj, F Huguet, AJC Wu, EM O'Reilly, C Winston, DL Reidy, PJ Allen, ...

Intrahepatic cholangiocarcinoma: expert consensus statement

SM Weber, D Ribero, EM O'Reilly, N Kokudo, M Miyazaki, TM Pawlik

JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or …

EM O'Reilly, C Walker, J Clark, KJ Brill, FW Dawkins, JC Bendell

Liver resection for metastatic colorectal leiomyosarcoma: a single center experience

W Faraj, J El-Kehdy, G El Nounou, S Deeba, H Fakih, M Jabbour, ...

Liver-directed conversion therapy in metastatic colon cancer

A Snyder, N Kemeny, A Shamseddine, A Al-Olayan, F El-Merhi, ...

Lymph node metastasis predicts disease recurrence in a single-center experience of 70 stages 1–3 appendix cancers: a retrospective review

GM Nash, JD Smith, L Tang, MR Weiser, LK Temple, E O’Reilly, LB Saltz, ...

nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).

MA Tempero, DB Cardin, A Biankin, D Goldstein, M Moore, EM O'Reilly, ...

Novel directions in neoadjuvant therapy for pancreas adenocarcinoma

A Yang, EM O’Reilly

Novel therapeutics for pancreatic adenocarcinoma

MA Lowery, EM O'Reilly

Overall survival and clinical characteristics in BRCA mutation carriers with stage I/II pancreatic cancer (PC).

T Golan, T Sella, MM Javle, A Borgida, EM O'Reilly, DP Kelsen, ...

P-185 Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT

M Tempero, D Cardin, A Biankin, D Goldstein, M Moore, E O'Reilly, ...

Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma

JM Herman, DT Chang, KA Goodman, AS Dholakia, SP Raman, ...

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic …

J Bendell, EM O'Reilly, MR Middleton, I Chau, H Hochster, A Fielding, ...

Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).

MA Lowery, DP Kelsen, SC Smith, M Moore, HL Kindler, T Golan, A Segal, ...

Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer.

RD Yaeger, A Cercek, EM O'Reilly, DL Reidy, NE Kemeny, T Wolinsky, ...

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

R Yaeger, A Cercek, EM O'Reilly, DL Reidy, N Kemeny, T Wolinsky, ...

Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC).

LC Connell, JJ Harding, MA Lowery, NE Kemeny, A Cercek, ...

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer …

EM O'Reilly, D Mahalingam, JM Roach, BC Schultes, ME Rosano, ...

The impact of chemotherapy on hospitalizations and emergency care in older adults with advanced cancer.

EB Elkin, C O'Neill, CL Atoria, EM O'Reilly, P Bach

Treatment, outcomes, and clinical trial participation in elderly patients with metastatic pancreas adenocarcinoma

D Li, M Capanu, HY Kenneth, MA Lowery, DP Kelsen, EM O'Reilly

Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)

M Tempero, D Cardin, AV Biankin, D Goldstein, M Moore, E O'Reilly, ...

25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance)

K Van Loon, K Owzar, C Jiang, HL Kindler, MF Mulcahy, D Niedzwiecki, ...

465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+ Gem) demonstrates …

A Kapoun, E O'Reilly, A Cohn, JC Bendell, L Smith, JH Strickler, W Gluck, ...

A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia

H Dbouk, S Mentha, D Mukherji, J Lee, A Haydar, A Shamseddine, ...